Aarti Drugs Limited (NSE:AARTIDRUGS)
India
· Delayed Price · Currency is INR 463.90
+1.75 (0.38%)
Jun 9, 2025, 11:29 AM IST
Aarti Drugs Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Other Revenue | - | -0 | - | 0 | - | Upgrade
|
| Revenue | 23,870 | 25,286 | 27,161 | 24,886 | 21,548 | Upgrade
|
| Revenue Growth (YoY) | -5.60% | -6.90% | 9.14% | 15.49% | 19.31% | Upgrade
|
| Cost of Revenue | 15,421 | 16,970 | 19,102 | 17,022 | 13,319 | Upgrade
|
| Gross Profit | 8,449 | 8,316 | 8,058 | 7,865 | 8,229 | Upgrade
|
| Selling, General & Admin | 1,121 | 1,047 | 933.07 | 840.53 | 815.37 | Upgrade
|
| Other Operating Expenses | 4,458 | 4,104 | 4,069 | 3,640 | 3,034 | Upgrade
|
| Operating Expenses | 6,137 | 5,666 | 5,505 | 4,981 | 4,348 | Upgrade
|
| Operating Income | 2,313 | 2,650 | 2,553 | 2,884 | 3,881 | Upgrade
|
| Interest Expense | -358.7 | -335.15 | -332.93 | -207.48 | -229.57 | Upgrade
|
| Interest & Investment Income | - | 24.97 | 7.02 | 23.16 | 36.2 | Upgrade
|
| Other Non Operating Income (Expenses) | 163.69 | 15.33 | 14.92 | 0 | -0 | Upgrade
|
| EBT Excluding Unusual Items | 2,118 | 2,355 | 2,242 | 2,700 | 3,688 | Upgrade
|
| Asset Writedown | - | - | - | - | -30.42 | Upgrade
|
| Other Unusual Items | - | - | - | - | 32.67 | Upgrade
|
| Pretax Income | 2,118 | 2,355 | 2,242 | 2,700 | 3,690 | Upgrade
|
| Income Tax Expense | 436.8 | 639.37 | 578.25 | 649.59 | 886.16 | Upgrade
|
| Earnings From Continuing Operations | 1,681 | 1,716 | 1,664 | 2,050 | 2,804 | Upgrade
|
| Minority Interest in Earnings | 0.62 | -1.73 | -0.48 | 0.43 | 0.15 | Upgrade
|
| Net Income | 1,682 | 1,714 | 1,663 | 2,050 | 2,804 | Upgrade
|
| Net Income to Common | 1,682 | 1,714 | 1,663 | 2,050 | 2,804 | Upgrade
|
| Net Income Growth | -1.90% | 3.07% | -18.89% | -26.88% | 98.31% | Upgrade
|
| Shares Outstanding (Basic) | 92 | 92 | 93 | 93 | 93 | Upgrade
|
| Shares Outstanding (Diluted) | 92 | 92 | 93 | 93 | 93 | Upgrade
|
| Shares Change (YoY) | -0.32% | -0.72% | - | -0.64% | - | Upgrade
|
| EPS (Basic) | 18.35 | 18.65 | 17.96 | 22.14 | 30.09 | Upgrade
|
| EPS (Diluted) | 18.35 | 18.65 | 17.96 | 22.14 | 30.09 | Upgrade
|
| EPS Growth | -1.58% | 3.82% | -18.89% | -26.41% | 98.31% | Upgrade
|
| Free Cash Flow | 674.2 | 1,326 | -314.97 | -815.61 | 667.19 | Upgrade
|
| Free Cash Flow Per Share | 7.36 | 14.42 | -3.40 | -8.81 | 7.16 | Upgrade
|
| Dividend Per Share | 1.000 | 1.000 | 1.000 | 1.000 | 2.500 | Upgrade
|
| Dividend Growth | - | - | - | -60.00% | 400.00% | Upgrade
|
| Gross Margin | 35.40% | 32.89% | 29.67% | 31.60% | 38.19% | Upgrade
|
| Operating Margin | 9.69% | 10.48% | 9.40% | 11.59% | 18.01% | Upgrade
|
| Profit Margin | 7.04% | 6.78% | 6.12% | 8.24% | 13.01% | Upgrade
|
| Free Cash Flow Margin | 2.82% | 5.24% | -1.16% | -3.28% | 3.10% | Upgrade
|
| EBITDA | 2,871 | 3,140 | 3,028 | 3,353 | 4,335 | Upgrade
|
| EBITDA Margin | 12.03% | 12.42% | 11.15% | 13.47% | 20.12% | Upgrade
|
| D&A For EBITDA | 557.8 | 489.77 | 475.43 | 469.4 | 453.3 | Upgrade
|
| EBIT | 2,313 | 2,650 | 2,553 | 2,884 | 3,881 | Upgrade
|
| EBIT Margin | 9.69% | 10.48% | 9.40% | 11.59% | 18.01% | Upgrade
|
| Effective Tax Rate | 20.63% | 27.15% | 25.79% | 24.06% | 24.01% | Upgrade
|
| Revenue as Reported | 24,034 | 25,326 | 27,182 | 25,000 | 21,593 | Upgrade
|
| Advertising Expenses | - | 23.3 | 11.67 | 13.5 | 9.81 | Upgrade
|
Updated Jan 29, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.